Montclair State University

Montclair State University Digital
Commons
Department of Psychology Faculty Scholarship
and Creative Works

Department of Psychology

9-13-2018

Vortioxetine Differentially Modulates MK-801-Induced Changes in
Visual Signal Detection Task Performance and Locomotor Activity
Todd M. Hillhouse
Weber State University

Christina R. Merritt
Virginia Commonwealth University

Douglas A. Smith
H. Lundbeck A/S

Manuel Cajina
H. Lundbeck A/S

Connie Sanchez
Alkermes Inc

See next page for additional authors
Follow this and additional works at: https://digitalcommons.montclair.edu/psychology-facpubs
Part of the Psychology Commons

MSU Digital Commons Citation
Hillhouse, Todd M.; Merritt, Christina R.; Smith, Douglas A.; Cajina, Manuel; Sanchez, Connie; Porter,
Joseph H.; and Pehrson, Alan, "Vortioxetine Differentially Modulates MK-801-Induced Changes in Visual
Signal Detection Task Performance and Locomotor Activity" (2018). Department of Psychology Faculty
Scholarship and Creative Works. 574.
https://digitalcommons.montclair.edu/psychology-facpubs/574

This Article is brought to you for free and open access by the Department of Psychology at Montclair State
University Digital Commons. It has been accepted for inclusion in Department of Psychology Faculty Scholarship
and Creative Works by an authorized administrator of Montclair State University Digital Commons. For more
information, please contact digitalcommons@montclair.edu.

Authors
Todd M. Hillhouse, Christina R. Merritt, Douglas A. Smith, Manuel Cajina, Connie Sanchez, Joseph H.
Porter, and Alan Pehrson

This article is available at Montclair State University Digital Commons: https://digitalcommons.montclair.edu/
psychology-facpubs/574

ORIGINAL RESEARCH
published: 13 September 2018
doi: 10.3389/fphar.2018.01024

Vortioxetine Differentially Modulates
MK-801-Induced Changes in Visual
Signal Detection Task Performance
and Locomotor Activity
Todd M. Hillhouse 1* , Christina R. Merritt 2 , Douglas A. Smith 2 , Manuel Cajina 3 ,
Connie Sanchez 4 , Joseph H. Porter 2 and Alan L. Pehrson 5*
1

Department of Psychology, Weber State University, Ogden, UT, United States, 2 Department of Psychology, Virginia
Commonwealth University, Richmond, VA, United States, 3 Lundbeck Research USA, Inc., Paramus, NJ, United States,
4
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, 5 Department of Psychology, Montclair State
University, Montclair, NJ, United States

Edited by:
Arjan Blokland,
Maastricht University, Netherlands
Reviewed by:
Andrzej Pilc,
Polish Academy of Sciences, Poland
Robert Warren Gould,
Vanderbilt University, United States
*Correspondence:
Todd M. Hillhouse
toddhillhouse@weber.edu
Alan L. Pehrson
pehrsona@montclair.edu
Specialty section:
This article was submitted to
Neuropharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 20 December 2017
Accepted: 23 August 2018
Published: 13 September 2018
Citation:
Hillhouse TM, Merritt CR, Smith DA,
Cajina M, Sanchez C, Porter JH and
Pehrson AL (2018) Vortioxetine
Differentially Modulates
MK-801-Induced Changes in Visual
Signal Detection Task Performance
and Locomotor Activity.
Front. Pharmacol. 9:1024.
doi: 10.3389/fphar.2018.01024

Attention impairment is a common feature of Major Depressive Disorder (MDD), and
MDD-associated cognitive dysfunction may play an important role in determining
functional status among this patient population. Vortioxetine is a multimodal
antidepressant that may improve some aspects of cognitive function in MDD patients,
and may indirectly increase glutamate neurotransmission in brain regions classically
associated with attention function. Previous non-clinical research suggests that
vortioxetine has limited effects on attention. This laboratory previously found that
vortioxetine did not improve attention function in animals impaired by acute scopolamine
administration, using the visual signal detection task (VSDT). However, vortioxetine
has limited effects on acetylcholinergic neurotransmission, and thus it is possible that
attention impaired by other mechanisms would be attenuated by vortioxetine. This
study sought to investigate whether acute vortioxetine administration can attenuate
VSDT impairments and hyperlocomotion induced by the non-competitive N-methylD -aspartate (NMDA) receptor antagonist MK-801. We found that acute vortioxetine
administration had no effect on VSDT performance on its own, but potentiated MK801-induced VSDT impairments. Furthermore, vortioxetine had no effect on locomotor
activity on its own, and did not alter MK-801-induced hyperlocomotion. We further
investigated whether vortioxetine’s effect on MK-801 could be driven by a kinetic
interaction, but found that plasma and brain exposure for vortioxetine and MK-801 were
similar whether administered alone or in combination. Thus, it appears that vortioxetine
selectively potentiates MK-801-induced impairments in attention without altering its
effects on locomotion, and further that this interaction must be pharmacodynamic in
nature. A theoretical mechanism for this interaction is discussed.
Keywords: vortioxetine, MK-801, visual signal detection task, locomotor activity, attention
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investigated vortioxetine’s effects on event-related potentials
(ERPs) assessed by electroencephalographic recordings during
a two-tone auditory discrimination task (Laursen et al., 2017).
Laursen et al. (2017) found that, while acute vortioxetine
administration did not alter behavioral responses to target and
oddball tones, it did significantly increase the amplitude of
hippocampal P3 ERPs, an analog of the human P300 ERP
that is putatively relevant for attention (Gray et al., 2004).
Thus, vortioxetine may increase some aspects of hippocampal
synchrony during attention-relevant tasks.
However, a recent paper from this laboratory investigated
the effects of vortioxetine in another model of attention, visual
signal detection task (VSDT) impairments induced by the
muscarinic acetylcholinergic receptor antagonist scopolamine.
This study demonstrated that, although acute vortioxetine
treatment was able to reverse scopolamine-induced deficits
in memory performance at clinically relevant doses, it was
unable to alter scopolamine-induced impairments in the VSDT
(Pehrson et al., 2016a). Importantly, acute administration of the
acetylcholinesterase inhibitor donepezil was able to significantly
attenuate scopolamine-induced VSDT impairments in this study
(Pehrson et al., 2016a). As an assessment of vortioxetine’s
general effects on attention function, this study could be
questioned based on the use of scopolamine as a platform
for inducing attention impairment. Although previous research
has consistently demonstrated that acute vortioxetine treatment
can modulate cholinergic neurotransmission by increasing
acetylcholine efflux (Mork et al., 2013; Pehrson et al., 2016a),
this increase is also consistently small and short-lived. Thus,
vortioxetine’s lack of an effect on scopolamine-induced VSDT
impairments may be related to its limited influence on cholinergic
neurotransmission.
One of several theories on the mechanism by which
vortioxetine influences cognitive function suggests that
vortioxetine administration indirectly increases glutamate
neurotransmission in brain regions such as the medial prefrontal
cortex (Riga et al., 2016, 2017), a brain region associated
with attention function in tasks such as the 3 choice serial
reaction time task (Totah et al., 2009). While this theory has
accumulated some supporting mechanistic evidence, there are
still relatively few studies that have directly evaluated a role
for altered glutamatergic neurotransmission in vortioxetine’s
effects on cognitive function. Thus, the current work was a
part of a multi-study project aimed at evaluating vortioxetine’s
effects on frontal cortex-dependent cognitive impairments
induced by dysregulation of glutamate neurotransmission.
Elsewhere, we have reported a study evaluating vortioxetine’s
effects on subchronic PCP-induced impairments in the AST,
a test of executive function (Pehrson et al., 2018). Given that
we are unaware of any studies that have evaluated a role for
this mechanism in behavioral measures of attention, the goal
of the present study was to evaluate vortioxetine’s effects on
VSDT impairments induced by acute administration of a noncompetitive NMDA receptor antagonist. Therefore, we decided
to investigate vortioxetine’s effects on VSDT deficits induced
by acute MK-801 administration, which has well-characterized
effects in this task (see Discussion, below). In addition, given

INTRODUCTION
Major Depressive Disorder (MDD) is a highly prevalent
psychiatric illness that is associated with marked functional
impairment (McCall and Dunn, 2003), and is a leading cause
of disability worldwide (Collins et al., 2011). Although MDD
is primarily seen as a disorder of mood, extant clinical data
suggests that MDD patients commonly present with severe
impairments in cognitive processes such as executive function
and attention (McIntyre et al., 2013). One study estimated that
more than a third of MDD patients are functioning at least
two standard deviations below average in one or more cognitive
domains (Gualtieri and Morgan, 2008), and several research
groups have found predictive relationships between MDDrelated cognitive dysfunction and either functional disability
or poor perceived workplace performance (McCall and Dunn,
2003; Jaeger et al., 2006; McIntyre et al., 2013). Although
many believe that these cognitive impairments withdraw when
mood symptoms are effectively treated, there is some evidence
that counters this narrative. For example, Hasselbalch et al.
(2011) conducted a systematic review of studies that investigated
cognitive function in remitted MDD patients, and reported that
significant impairment in tests of one or more cognitive domains
(attention, executive function, memory, or global function) was
observed in 9 of the 11 studies. These observations suggest
that treatment of MDD-related mood dysfunction alone is
insufficient to engender full functional recovery for many MDD
patients. Therefore, identifying biological mechanisms capable of
remediating MDD-associated impairments in cognitive function
is an important strategic goal to improve functional outcomes in
MDD patients.
Vortioxetine is an antidepressant featuring a complex
pharmacological profile consisting of inhibition at the serotonin
(5-HT) transporter (SERT), antagonism at 5-HT1D , 5-HT3 ,
and 5-HT7 receptors, partial agonism at 5-HT1B receptors,
and agonism at 5-HT1A receptors. Clinical evidence from
several randomized placebo-controlled trials suggests that
vortioxetine attenuates impairments in executive function and
speed of processing (McIntyre et al., 2016). Additionally, in
a predefined secondary outcome in one randomized, placebocontrolled trial, vortioxetine significantly improved scores in the
perceived deficits questionnaire attention/concentration subscale
(Mahableshwarkar et al., 2015), a subjective measure of attention
performance. Non-clinical studies have also demonstrated that
vortioxetine improves cognitive performance in a variety of
rodent-based models of executive function. Wallace et al. (2014)
demonstrated that vortioxetine attenuated impairments in the
attentional set shifting task (AST) induced by 5-HT depletion
or chronic intermittent cold stress in rats. Additionally, this
laboratory recently demonstrated that vortioxetine reverses AST
impairments induced by subchronic administration of the noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist
phencyclidine (Pehrson et al., 2018).
Although non-clinical literature supports the idea that
vortioxetine improves behavioral measures of executive function
in deficit models, the non-clinical data on vortioxetine’s influence
on attention has been equivocal at best. A recent study
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signal light, food hopper, two retractable levels, and a house
light. The front panel of the operant chamber housed the signal
light which was mounted directly above a food hopper and
two retractable levers positioned on either side of the food cup.
Additionally, the back panel was equipped with a house light that
provided a background illumination (except during a time out
period).

that the pattern of 5-HT3 receptor expression is relatively
circumscribed in the forebrain, and is not strongly present in
motor function circuits such as the striatum (Raffa et al., 1989;
Morales et al., 1998; Pehrson et al., 2016b), vortioxetine’s effects
on glutamate neurotransmission should be similarly limited to
frontal cortex-dependent tasks, and would not be present in
assessments of motor function. Therefore, we made the following
hypotheses: (1) vortioxetine will reverse behavioral impairments
in the VSDT (a test of attention) induced by the NMDA receptor
antagonist MK-801, and (2) vortioxetine will not alter locomotor
activity induced by MK-801.

Locomotor Activity
Habituation and experimental sessions were conducted in
four standard open field activity chambers enclosed within
sound attenuating cubicles (Med-Associates). Each chamber was
equipped with three 16-beam IR arrays, which tracked the rats
throughout the chambers, and a house light. Activity Monitor
(version 7; Med-Associates) was used to collect the data provided
from the three 16-beam IR arrays.

MATERIALS AND METHODS
Subjects
A total of 55 adult male Sprague-Dawley rats (Harlan
Laboratories Inc., Frederick, MD, United States) weighing
between 225 and 350 g at the start of the experiment. Of these,
15 rats were used in the VSDT experiment (Harlan Laboratories
Inc., Frederick, MD, United States), 16 rats were used for the
locomotor activity experiment (Harlan Laboratories), and 24 rats
were used for drug exposure studies (Charles River Laboratories,
Wilmington, MA, United States). Rats were housed individually
in a temperature- and humidity-controlled environment on a
12-h/12-h light/dark cycle (lights on 0600 h). All experimental
procedures were conducted during the light portion of the cycle.
Except where noted below, animals were given ad libitum access
to food and water. In addition, upon arrival at the vivarium,
all rats were given a 5–7-day acclimation period before any
experimental procedures began. All experimental procedures
were approved by the Institutional Animal Care and Use
Committee at Virginia Commonwealth University or Lundbeck
Research USA, Inc. prior to the start of experiments, and were
conducted in accordance with National Institutes of Health
Guide for the Care and Use of Laboratory Animals (Institute of
Laboratory Animal Resources, 2011).

Drug Exposure Studies
Drug exposure in plasma and brain tissue was measured using
an Aria TLX2 liquid chromatography system (Thermo Electron,
San Jose, CA, United States) coupled with a TSQ Quantum Ultra
mass spectrometer (Thermo Electron).

Behavioral Procedures
Visual Signal Detection Task
Food restriction
Prior to the start of VSDT experiments, rats were maintained
on free-feeding as described above. Based on weights measured
during this period, a target weight was calculated for each
individual, set to 85% of free-feeding weight. Daily access to
food was restricted so each rat’s actual body weight closely
approximated the calculated target weight. Water was available
ad libitum in home cages at all times.

VSDT training
The rats were trained and tested according to procedures
consistent with previously published experiments (Hillhouse and
Prus, 2013; Hillhouse et al., 2015; Pehrson et al., 2016a). Each trial
started with both the house light and a variable-intensity signal
light on. The combined background illumination of these lights
during this phase of training was 0.9 lux. During training, each
trial started with a consistent pre-signal interval of 4 s, during
which the lighting intensity was unchanged. After the pre-signal
interval, rats experienced either a “blank” or “signal” trial for
500 ms. For blank trial conditions, there was no change in the
signal light intensity for 500 ms. However, signal trial conditions
featured a 1.5 lux increase in illumination intensity of the signal
light for 500 ms (to a total intensity of 2.4 lux). A post-signal
interval of 1 s followed the signal (or blank) segment of the
trial during which time the chamber remained at the 0.9 lux
background illumination.
Following the post-signal interval, the left and right levers
were extended into the chamber. If a rat pressed the signal-lever
(randomly assigned as either the right or left lever) after a signal
trial it was recorded as a “hit” and the rat received a food pellet. If
a rat pressed the blank-lever during a blank trial it was recorded
as a correct rejection and the rat received a food pellet. Levers

Drugs and Chemicals
Vortioxetine HBr was obtained from Lundbeck Research USA,
Inc. (+) MK-801 hydrogen maleate was obtained from Sigma
Aldrich (St. Louis, MO, United States), while 2-hydroxypropylbeta-cyclodextrin was obtained from Roquette America (Keouk,
IA, United States). Vortioxetine was dissolved in a 20%
(w/v) solution of 2-hydroxypropyl-beta-cyclodextrin (20%CD)
at 5 mg/mL concentration and injected subcutaneously (s.c.) at
a 2 mL/kg volume, for a final dose of 10 mg/kg. MK-801 was
dissolved in water at 0.1 or 0.2 mg/mL and injected s.c at a
1 mL/kg volume, for a final dose of 0.1 or 0.2 mg/kg. The specific
doses and injection timing for each experiment are discussed
below. All doses refer to the mass of the free base, not the salt.

Apparatus
Visual Signal Detection Task
Training and experimental sessions were conducted in four
standard operant chambers enclosed within sound attenuating
cubicles (Med-Associates). Each chamber was equipped with a
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influence of a drug. After the habituation period, rats received
an injection of either 20%CD (2 mL/kg, s.c.) or 10 mg/kg
vortioxetine (s.c.) and immediately placed back into the open
field chamber for the second activity monitoring phase, which
lasted 30 min. Immediately after the second monitoring phase
was completed, rats were given a second injection that consisted
of either saline (1 mL/kg, s.c.) or 0.2 mg/kg MK-801 (s.c.). The
0.2 mg/kg MK-801 dose was chosen on the basis of evidence
that it induces robust hyperlocomotion (Ogren and Goldstein,
1994; Scorza et al., 2008), while lower doses produce less reliable
effects on locomotion (Amalric et al., 1994; Druhan et al., 1996;
Scorza et al., 2008). Rats were immediately placed back into the
activity chamber for 90 min. Locomotor testing was conducted
using a within-subjects design, with at least a 1-week washout
period between sessions. The order of drug combinations was
determined by a randomized Latin-square design, and thus
each animal in the LMA study was present in each treatment
condition locomotor chambers were cleaned between each group
of animals.

were retracted after a response or 5 s (whichever occurred first).
If rats failed to make a response in 5 s, then it was counted
as an omission. Incorrect responses (i.e., blank-lever during a
signal trial or signal-lever during a blank trial) and trial omissions
resulted in no food pellet delivery and a 2 s time-out (all lights
in test chamber turned off including the house light). Rats were
trained until a criterion of ≥70% choice accuracy was obtained
for 3 consecutive sessions.

VSDT testing
Test sessions were identical to training sessions except that 3
signal intensities were used (i.e., 0.4, 0.6, and 1.5 lux increase
above blank conditions, order randomized) and pre-signal
interval delays of 3, 6, and 12 s (order randomized) were used.
Test sessions consisted of 90 blank trials and 90 signal trials (i.e.,
30 low, 30 moderate, and 30 high signal intensity trials). Animals
received at least one training session immediately preceding a
test session. Test sessions were conducted no more than twice
a week (typically Tuesdays and Fridays) and were separated
by at least 72 h to allow for drug washout. On test days,
animals were injected with vehicle [20% (w/v) aqueous solution
of parenteral grade 2-hydroxypropyl-beta-cyclodextrin, 60 min
s.c.] or vortioxetine (10 mg/kg, 60 min s.c.) followed by either
MK-801 (0.1 mg/kg, 30 min s.c.) or vehicle (0.9% saline 30 min
s.c.) prior to test session start. The order of drug combinations
was determined by a randomized Latin-square design, and thus
each animal in the VSDT study was present in each treatment
condition. Drug doses and pretreatment times were based on
published literature. In the case of MK-801, the doses and
injection timing have previously demonstrated robust behavioral
effects in the VSDT without producing pronounced motor
suppression (Rezvani et al., 2008; Levin et al., 2011; Hillhouse
and Porter, 2014; Leiser et al., 2014; Hillhouse et al., 2015;
Pehrson et al., 2016a). Preliminary experiments demonstrated
that lower doses of MK-801failed to produce reliable behavioral
impairments. Thus, these lower doses were deemed to be
unacceptable for use in a randomized Latin square experimental
design. In the case of vortioxetine, the 10 mg/kg (1 h s.c.) dose
and injection timing was chosen because it has been extensively
characterized in pharmacological, neurochemical, and behavioral
cognition models, and is thought to represent the top of the
clinically relevant dose range from a mechanistic perspective
(Pehrson et al., 2013b, 2016a, 2018; du Jardin et al., 2014; Jensen
et al., 2014; Leiser et al., 2014).

Drug Exposure Study Methods
In order to investigate whether vortioxetine and MK-801 have
any pharmacokinetic interactions, studies were conducted to
examine vortioxetine and MK-801 exposure in plasma and brain
tissue. Rats in this experiment were randomly assigned to one
of three groups. In the first group, rats received an injection
of 20%CD (2 mL/kg, 60 min s.c.) followed by 0.1 mg/kg MK801 (30 min s.c.). Rats in the second group received injections
of 10 mg/kg vortioxetine (60 min s.c.) followed by saline
(1 mL/kg, 30 min s.c.). The final group received injections of
10 mg/kg vortioxetine (60 min s.c.) followed by 0.1 mg/kg MK801 (30 min s.c.). These injection times are identical to those used
in behavioral testing.
At the appropriate time after injection, rats were deeply
anesthetized using CO2 and killed by decapitation. Blood and
brain tissue were collected and processed as described elsewhere
(Pehrson et al., 2016a). Vortioxetine and MK-801 exposure levels
were detected using a liquid chromatography/mass spectrometry
system. The methods used for detecting exposure levels were
as described previously (Pehrson et al., 2016a), with one
modification. Spectra for MK-801 were acquired in positive
selected reaction monitoring mode with the following settings:
the parent mass (222.13 m/z) and daughter ion 1 (203 m/z) were
detected at 40 collision energy (CE) with a tube lens of 115.
Daughter ion 2 (205 m/z) was detected at 25 CE with tube lens
set at 115.

Locomotor Activity (LMA) Studies
LMA Training
Each rat received a total of seven habituation training sessions
over the course of 2 weeks. For these habituation sessions, rats
were placed in the center of the open field chamber and were
allowed to explore for 60 min. After the seven habituation
sessions, each rat was moved to the experimental phase of the
study.

Statistics
Visual Signal Detection Task
The dependent variables for the VSDT task were as follows:
(1) Percent hits = (number of correct responses on signal
trials/the number of signal trials completed) × 100. (2) Percent
correct rejections = (number of correct responses on blank
trials/the number of blank trials completed) × 100. (3) Response
latency = total time elapsed from when the levers were extended
to when a lever press occurred/the number of trials completed
(these data were collapsed for signal and blank trials). (4)

LMA Testing
Test sessions consisted of three separate phases. The first phase
consisted of a 60-min habituation period in which animals were
placed in activity chambers and were monitored without the
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were evenly distributed across light intensity for MK-801
alone (1.3 lux = 2.07 ± 1.86; 1.5 lux = 1.73 ± 1.74; 2.4
lux = 1.47 ± 1.40) and the combination of vortioxetine and
MK-801 (1.3 lux = 7.40 ± 2.04; 1.5 lux = 7.13 ± 2.00; 2.4
lux = 6.13 ± 1.98). The combination of vortioxetine and MK-801
produced a significant increase in the response latency for correct
rejections [F(3,42) = 30.82, P < 0.001: Figure 1D] and response
omissions [F(3,42) = 8.52, P < 0.001: Figure 1F]. Treatment with
vortioxetine alone did not alter response latency (percent hit or
correct rejection), or response omissions.

Response omissions = total number of trials where no response
occurred (these data were collapsed across signal and blank
trials). A two-factor repeated measures ANOVA was conducted
for percent hit with signal intensity and treatment condition as
factors. One-way repeated measures ANOVAs were used to assess
the effect of treatment condition on percent correct rejections,
response latency, or trial omissions.

Locomotor Activity
The dependent variables for the locomotor activity studies were
as follows: horizontal beam breaks and rearing (vertical beam
breaks). These dependent measures were analyzed using twofactor repeated measures ANOVAs, with behavioral epoch and
treatment as within-subjects factors. Where appropriate, these
ANOVAs were followed by Tukey post hoc tests.

Locomotor Activity
Table 1 represents the effects of vortioxetine, MK-801, or
combinations thereof on locomotor activity. Analysis of the
horizontal activity dependent measure using two factor repeated
measures ANOVAs found significant main effects for treatment
group [F(3,45) = 22.07, p < 0.001] and behavioral epoch
[F(2,30) = 30.94, p < 0.001], as well as a significant interaction
between these factors [F(6,90) = 22.34, p < 0.001]. Post hoc
analysis revealed that, within the baseline behavioral epoch,
there were no significant differences between the treatment
groups in terms of horizontal activity. Similarly, during the
second behavioral epoch, after injection with either vehicle or
vortioxetine, no significant differences in horizontal activity
were detected. However, in the final behavioral epoch, after
injection with either vehicle or MK-801, some notable differences
were observed between treatment groups. Specifically, both the
vehicle + MK-801 and the vortioxetine + MK-801 treatment
groups exhibited significantly more horizontal activity than
the vehicle + vehicle or vortioxetine + vehicle treatment
groups (p < 0.001). No differences were observed between the
vehicle + MK-801 and vortioxetine + MK-801 treatment groups.
Analysis of the rearing dependent measure using a two factor
repeated measures ANOVA revealed a significant main effect
for behavioral epoch [F(2,30) = 14.97, p < 0.001], but not for
treatment group [F(3,45) = 1.18, n.s.]. However, a significant
interaction between the treatment group and behavioral epoch
factors was observed [F(6,90) = 3.04, p < 0.01]. Again, post hoc
analysis failed to reveal any significant differences in rearing
behavior between the treatment groups during the baseline
epoch, or during the second epoch (after vehicle or vortioxetine
administration). However, during the final behavioral epoch
(after vehicle or MK-801 administration), we observed significant
increases in rearing behavior in the vehicle + MK-801
group compared to the vehicle + vehicle (p < 0.001) and
vortioxetine + vehicle (p < 0.01) treatment groups. The
vortioxetine + MK-801 group also exhibited significantly more
rearing behavior than the vehicle + vehicle group (p < 0.05), but
was not significantly different from either the vehicle + MK-801
group or the vortioxetine + vehicle group.

Drug Exposure
MK-801 and vortioxetine concentrations in plasma were
expressed in nM or µM, respectively, while concentrations in
brain tissue were expressed in nmol/kg or µmol/kg. Brain to
plasma exposure ratios were calculated by dividing a given brain
concentration by the relevant plasma concentration. Statistical
analysis of exposure data was conducted using independent
samples t-tests.

RESULTS
Visual Signal Detection Task
Figure 1 represents the effects of vortioxetine, MK-801, and
combinations thereof on VSDT performance. Analysis of the
data on the percent hits dependent measure (Figure 1A)
found a significant main effect of stimulus intensity light
[F(2,28) = 130.5, P < 0.001] and treatment group [F(3,42) = 8.34,
P < 0.001], as well as a significant interaction between
these factors [F(6,84) = 7.25, P < 0.001]. Under control
conditions, the expected stimulus intensity-dependent increase
in percent hits was observed. The 10 mg/kg vortioxetine
(1 h s.c.) + vehicle condition had no significant effects
on performance by comparison to the control condition.
Treatment with vehicle + 0.1 mg/kg MK-801 (30 min s.c.)
induced significant impairments on the percent hits dependent
measure compared to vehicle control at the 1.5 and 2.4
lux stimulus intensities, but not at the 1.3 lux stimulus
intensity. The 10 mg/kg vortioxetine + 0.1 mg/kg MK-801
treatment group was also significantly impaired compared to
vehicle controls at the 1.5 and 2.4 lux stimulus intensities,
however, at the 2.4 lux stimulus intensity this group was also
significantly more impaired than the vehicle + 0.1 mg/kg
MK-801 treatment group. Similar effects were found on the
remaining dependent variables. MK-801 (0.1 mg/kg) alone
significantly reduced correct rejection accuracy [F(3,42) = 14.79,
P < 0.001: Figure 1B] and significantly increased response
latency for percent hit [F(3,42) = 35.62, P < 0.001: Figure 1C];
whereas, the combination of 10 mg/kg vortioxetine + 0.1 mg/kg
MK-801 produced a greater impairments than MK-801 alone
[F(3,42) = 7.52, P < 0.001; Figure 1E). The response omissions
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Drug Exposure
Vortioxetine Exposure
Drug exposure data after treatment with 10 mg/kg vortioxetine
(1 h s.c.), 0.1 mg/kg MK-801 (30 min s.c.), or the combination
are presented in Table 2. Exposure to vortioxetine in plasma
[t(14) = 0.045, n.s.] and brain [t(14) = 0.11, n.s.] were similar
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FIGURE 1 | Vortioxetine potentiates MK-801-induced visual signal detection task impairments, but has no effects on its own. Left-side panels represent dependent
measures related to signal trials, while those on the right represent dependent measures related to blank trials. (A,B) Represent hits or correct rejections,
respectively. (C,D) Represent response latencies recorded during the relevant trial type, while (E,F) represent the frequency of omissions recorded during each trial
type. 0.1 mg/kg MK-801 administration (30 min s.c.) induced significant, signal intensity-dependent impairments in hits (A), correct rejections (B), and increased
response latencies during signal trials (C) compared to vehicle controls. 10 mg/kg vortioxetine (1 h s.c.) did not significantly alter performance in any dependent
measure on its own. The combination of vortioxetine + MK-801 induced significantly greater impairments in hits, correct rejections, response latencies (C,D), and
omissions (E,F). Asterisks represent significant differences from the Veh + Veh group (∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001). Plus signs represent significant
differences from the Vor + Veh group (+ P < 0.05, ++ P < 0.01, +++ P < 0.001). Number signs represent significant differences from the Veh + MK-801 group
(# P < 0.05, ## P < 0.01, ### P < 0.001).

MK-801 Exposure

whether examined in animals from the vortioxetine + vehicle
or vortioxetine + MK-801 treatment groups. Additionally, the
brain:plasma ratio for vortioxetine was not significantly different
between these treatment groups [t(14) = 0.12, n.s.].
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Similarly, MK-801 exposure data in animals treated with
vehicle + 0.1 mg/kg MK-801 was not significantly different
from that observed in animals treated with 10 mg/kg
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TABLE 1 | Vortioxetine does not alter MK-801-induced hyperactivity.
Behavioral epoch

Treatment group
Veh + Veh

Veh + MK-801

Vor + Veh

Vor + MK-801

1110 ± 108

Horizontal activity
Baseline

1120 ± 117

1096 ± 156

1218 ± 112

After Veh or Vor

478 ± 43

485 ± 47

610 ± 52

After Veh or MK-801

610 ± 83

16637 ± 3470∗∗∗,+++

599 ± 66
17318 ± 2865∗∗∗,+++

654 ± 96

Rearing
Baseline

99 ± 11

88 ± 10

100 ± 9

93 ± 11

After Veh or Vor

39 ± 4

38 ± 5

49 ± 4

44 ± 5

After Veh or MK-801

50 ± 8

61 ± 10

89 ± 24∗

111 ± 25∗∗∗,++

Locomotor activity was observed in three contiguous epochs on a given test day: a 60-min baseline, a 30-min session starting immediately after vehicle or 10 mg/kg
vortioxetine (s.c.), and a 90-min session starting immediately after vehicle or 0.2 mg/kg MK-801 (s.c). MK-801 administration induced significant increases in horizontal
activity that was not modified by pretreatment with vortioxetine. No treatment induced significant changes in rearing behavior. Data are presented as Mean ± SEM.
∗ P < 0.05 compared to the Veh + Veh treatment groups. Asterisks represent significant differences from the Veh + Veh group (∗∗ P < 0.01, ∗∗∗ P < 0.001). Plus signs
represent significant differences from the Vor + Veh group (+ P < 0.05, ++ P < 0.01, +++ P < 0.001).
TABLE 2 | No pharmacokinetic interactions are present between acute vortioxetine and MK-801.
Treatment Group

Vortioxetine

MK-801

Plasma (µM)

Brain (µmol/kg)

Brain:Plasma

2.3 ± 0.1

44.6 ± 7.6

20.1 ± 3.6

0

0

0

0

0

0

67 ± 10

960 ± 220

15.2 ± 2.6

2.3 ± 0.15

43.4 ± 3.5

19.6 ± 1.5

66 ± 8.6

1340 ± 240

19.7 ± 2.3

Vortioxetine (10 mg/kg 60 min s.c.)
MK-801 (0.1 mg/kg, 30 min s.c.)
Vortioxetine (10 mg/kg, 60 min s.c.) +
MK-801 (0.1 mg/kg, 30 min s.c.)

Plasma (µM)

Brain (µmol/kg)

Brain:Plasma

Using administration routes, timing, and doses identical to those used in the visual signal detection task, vortioxetine administration had no significant effects on MK-801
plasma exposure, brain exposure, or brain:plasma ratio. Similarly, MK-801 had no significant effects on vortioxetine plasma exposure, brain exposure, or brain:plasma
ratio. Data are presented as Mean ± SEM. The sample size was 7–8 animals per group.

vortioxetine + 0.1 mg/kg MK-801 in plasma [t(14) = 0.02,
n.s.], or brain [t(13) = 1.09, n.s.]. Furthermore, the brain:plasma
ratio for MK-801 was not significantly different between these
two treatment groups [t(13) = 1.30, n.s.].

Vortioxetine Does Not Alter Attention
Performance Under Normal Conditions
We observed that 10 mg/kg vortioxetine (1 h s.c.), which
represents the top of the clinically relevant dose range based
on SERT occupancy (Stenkrona et al., 2013; Leiser et al.,
2014), does not alter VSDT performance in normal rats. This
result is consistent with previous work from this laboratory,
which also demonstrated that this vortioxetine dose does not
alter VSDT performance (Pehrson et al., 2016a). Laursen et al.
(2017) investigated vortioxetine’s effects in a two-tone auditory
discrimination task, another putative measure of attention
performance, and found that vortioxetine did not alter rodents’
performance at the 3 and 10 mg/kg doses. It should be
noted that vortioxetine significantly increased the amplitude
of hippocampal P3 ERPs, which may be related to attention
processing. However, these data suggest that vortioxetine
consistently does not affect behavioral attention measures in
unimpaired animals.
This conclusion should be viewed cautiously from several
perspectives. First, to date vortioxetine has been assessed in
a limited number of validated behavioral attention models. It
remains possible, although unlikely, that vortioxetine will alter
attention in other models. Additionally, vortioxetine has yet to be
assessed in a model of MDD-related attention deficits. Finally, the
current study evaluated vortioxetine’s effects under acute dosing
conditions rather than chronic administration, which would be

DISCUSSION
This study examined the effects of vortioxetine and MK801, administered alone and in combination, on attention
(measured in the VSDT) and locomotor activity. We
observed that the selective glutamatergic NMDA receptor
antagonist MK-801 impaired VSDT performance and elicited
marked hyperlocomotion at the doses used. Vortioxetine
had no effect on VSDT performance alone. However, when
administered in combination with MK-801, vortioxetine
pre-treatment exacerbated MK-801’s effects. This effect
cannot be explained by a pharmacokinetic interaction,
given that vortioxetine pretreatment had no significant
effects on MK-801 exposure in brain or plasma. Thus,
the interaction between vortioxetine and MK-801 must be
pharmacodynamic in nature. We further found that vortioxetine
does not affect MK-801-induced hyperlocomotion, which
may imply that vortioxetine’s interaction with MK-801 is not
system-wide, but instead is circumscribed to specific brain
circuits.
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interact with MK-801, potentiating its effects on attention but not
locomotion.
This result is somewhat surprising in light of evidence that
acute or subchronic vortioxetine treatment reverses subchronic
phencyclidine-induced impairments in memory and the AST
(Pehrson et al., 2018). Although the AST and VSDT examine
separate cognitive domains, executive function and attention,
respectively, portions of both the AST and the VSDT are thought
to depend on frontal cortex function. Thus, based on these
data it is apparent that vortioxetine administration does not
universally reverse the effects of NMDA receptor antagonists
on frontal cortex-dependent cognitive tasks. Instead, it appears
that vortioxetine has complex interactions with non-competitive
NMDA receptor antagonists. Based on the accumulated data, the
mechanisms driving these differences in vortioxetine’s effects are
unclear. It may be that vortioxetine modulates the specific frontal
cortex sub-regions that these separate cognitive domains depend
on differently, or it may be a difference in vortioxetine’s effects
under the acute vs. subchronic effects of non-competitive NMDA
receptor antagonists. More study is required to differentiate
between these possibilities.
We considered two possible mechanistic explanations for
the selective vortioxetine-MK-801 interaction mentioned
above. First, vortioxetine and MK-801 might interact
pharmacokinetically, wherein the presence of vortioxetine
would increase brain MK-801 exposure. Alternately, the
vortioxetine-MK-801 interaction could be pharmacodynamic in
nature, wherein vortioxetine’s receptor actions would increase
MK-801’s ability to access its binding site. In light of the selective
effect of vortioxetine on MK-801-induced attention impairments
but not hyperlocomotion, we considered it unlikely that a
pharmacokinetic interaction was the culprit. If vortioxetine
caused an increase in MK-801 brain exposure, it would occur
everywhere in the brain, and therefore would not be selective for
one behavior over another.
In order to empirically evaluate whether a pharmacokinetic
interaction between vortioxetine and MK-801 was present,
we examined plasma and brain exposure after administration
of vortioxetine, MK-801, or combinations thereof. We found
no differences in MK-801 or vortioxetine exposure between
these conditions. Therefore, the vortioxetine-MK-801 interaction
observed in VSDT impairments must be pharmacodynamic in
nature.

more consistent with its clinical use. Thus, in order to fully
understand whether vortioxetine has effects on attention function
that could be relevant for MDD, future studies should focus on
evaluating its effects in MDD-related models of attention deficit
using chronic administration.
There is a paucity of studies that have investigated
antidepressant effects on attention, and the available data
has generally used normal animals. Several research groups
have demonstrated that serotonin reuptake inhibitors such as
citalopram (Baarendse and Vanderschuren, 2012; Humpston
et al., 2013), fluoxetine (Humpston et al., 2013), or paroxetine
(Humpston et al., 2013) either do not modify attention
performance, or induce impairments such as increased omissions
or response latency. From this perspective, vortioxetine’s limited
effects on attention in normal rodents are consistent with the
actions of other serotonergic antidepressants.

Acute Treatment With MK-801 Impairs
VSDT Performance and Induces
Hyperlocomotion
We observed that acute administration of 0.1 mg/kg MK801 induced a signal intensity-dependent impairment in hits,
increased the response latency for hits, and reduced correct
rejections. These effects are consistent with the literature of
non-competitive NMDA receptor antagonist effects on attention
function. Other labs have demonstrated that acute MK-801
(Howe and Burk, 2007; Rezvani et al., 2009; Levin et al.,
2014) or ketamine treatment (Hillhouse et al., 2015) induces
similar VSDT impairments. Furthermore, several labs have
demonstrated similar MK-801-induced impairments in alternate
behavioral attention models after either systemic (Auger et al.,
2017) or intra-cerebral microinjection into the mPFC (Auger
et al., 2017), or the anterior cingulate cortex (Pehrson et al.,
2013a).
In the locomotor activity portion of the current study, we
demonstrated that systemic treatment with MK-801 induced
hyperlocomotion in a manner that is consistent with published
literature (Amalric et al., 1994; Ogren and Goldstein, 1994; HatipAl-khatib et al., 2001; Scorza et al., 2008).

Acute Pretreatment With Vortioxetine
Selectively Potentiates MK-801’s Effects
on Attention via a Pharmacodynamic
Interaction

A Proposed Pharmacodynamic
Mechanism for Vortioxetine’s Selective
Influence on MK-801-Induced Attention
Impairments: Regionally Selective
Increases in Depolarization of NMDA
Receptor-Expressing Neurons

Contrary to our hypothesis that vortioxetine administration
would attenuate MK-801’s effects on VSDT performance,
we observed that vortioxetine potentiated these effects on
several VSDT dependent measures, including hits, correct
rejections, response latencies, and omissions. However, when
the combination of vortioxetine and MK-801 was administered
in locomotor activity, we observed no difference compared to
the MK-801 alone treatment group. We consider it unlikely
that this lack of a difference in hyperlocomotion is due to a
ceiling effect, given that other research groups have observed
MK-801-induced increases in horizontal activity up to 0.5 mg/kg
(Amalric et al., 1994). Thus, vortioxetine appears to selectively
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We propose that vortioxetine’s pharmacodynamic interaction
with MK-801 is mediated by a regionally selective increase
in membrane depolarization in NMDA receptor-expressing
neurons. This theoretical mechanism is based on three premises:
(1) MK-801-induced behavioral alterations in attention and
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agonist-dependent (Huettner and Bean, 1988; Halliwell et al.,
1989). These voltage-dependent pharmacological actions of MK801 are due to the position of the non-competitive NMDA
receptor antagonist binding site being positioned behind a Mg2+
ion inside the channel (Huettner and Bean, 1988). Thus, MK801 binding requires receptor activation, and sufficient cellular
membrane depolarization to expel the Mg2+ ion from the
channel.

locomotor behavior depend on separate brain circuits, (2)
MK-801’s pharmacological effects are receptor activation- and
voltage-dependent, (3) vortioxetine may induce regionally
selective increases in excitatory neurotransmission, thereby
having different effects on neuronal activity in different brain
regions. Evidence in favor of each of these premises is presented
below.
Premise 1: MK-801-induced behavioral alterations in
attention and locomotion depend on separate brain circuits.

Premise 3: Vortioxetine induces indirect increases in
excitatory neurotransmission that are likely to be regionally
selective.

It is well known that systemic MK-801 administration
impairs attention models and induces hyperlocomotion. MK801’s brain region-specific effects in these behavioral models
are less well characterized, however some data is available. In
behavioral attention measures such as the 3 choice serial reaction
time (3CSRT) task, electrophysiological data demonstrates that
the anterior cingulate cortex (ACC) and medial prefrontal
cortex (mPFC) play a role in representing attention-relevant
information in rats (Totah et al., 2009), and intra-ACC MK801 injections selectively increased omissions in the 3CSRT
task without altering the accuracy (Pehrson et al., 2013a). In
the sustained attention task, intra-mPFC MK-801 injections
impaired vigilance during high-difficulty conditions (Auger
et al., 2017). We could not find any study that evaluated noncompetitive NMDA receptor antagonists in the VSDT using
region-specific microinjections; thus, it is unknown whether
these effects translate to this attention model. But overall, NMDA
receptors in frontal cortex regions seem to mediate portions of
attention performance.
However, the available data suggest that the frontal cortex
does not mediate MK-801-induced hyperlocomotion, whereas
the nucleus accumbens (NAc) may play an important role. Scorza
et al. (2008) demonstrated that systemic MK-801 injections
induced robust locomotor increases, and that electrolytic
mPFC lesions did not alter MK-801-induced hyperlocomotion.
However, MK-801 infusions into the NAc increased locomotor
behavior (Raffa et al., 1989), and 6-OHDA lesions of the NAc
block systemic MK-801-induced hyperlocomotion (Hatip-Alkhatib et al., 2001). Taken together, these data suggest that
although MK-801-induced attention impairment are mediated in
part by the frontal cortex, its effects on locomotion are at least
partially mediated by subcortical regions such as the NAc.

Although vortioxetine has a purely serotonergic pharmacological
profile within the clinically relevant dose range (Leiser et al.,
2014), there is an accreting narrative suggesting that this
compound exerts complex effects on excitatory and inhibitory
neurotransmission that may vary markedly across brain regions.
At the doses used here, vortioxetine fully antagonizes 5-HT3
receptors (Leiser et al., 2014), which are excitatory ion channels
selectively expressed in non-parvalbumin-positive GABAergic
interneurons (Morales et al., 1996; Morales and Bloom, 1997).
Immunohistochemical and autoradiographic expression studies
have demonstrated that 5-HT3 receptors have a circumscribed
expression pattern, with relatively high expression in the mPFC,
but low expression levels in striatal regions such as the NAc
(Morales et al., 1998). Thus, 5-HT3 receptors can be thought of
as a serotonin-mediated fast excitatory drive on non-fast-spiking
GABAergic interneurons. In the frontal cortex and hippocampus,
where these GABAergic interneurons modulate glutamatergic
pyramidal neuron function, 5-HT3 receptor antagonism can be
expected to disinhibit glutamate neurotransmission (reviewed
in Dale et al., 2016; Pehrson et al., 2016b). However, in the
NAc, where there is very little 5-HT3 receptor expression, a local
disinhibition of this sort would not be expected to occur (Pehrson
et al., 2016b).
Recent mechanistic data from electrophysiology studies
support portions of this theory. Dale et al. (2014) demonstrated
in hippocampal slices that vortioxetine blocks 5-HT3
receptor agonist-evoked inhibitory postsynaptic currents
(IPSCs) recorded in pyramidal neurons, suggesting that
vortioxetine blocked 5-HT3 receptor-mediated GABAergic
neurotransmission (also see (Dale et al., 2017). Additionally,
a separate group of researchers found that acute or chronic
vortioxetine increased cortical pyramidal neuron firing rates
(Riga et al., 2016, 2017). This effect was also observed using the
selective 5-HT3 receptor antagonist ondansetron, but not the
serotonin reuptake inhibitor escitalopram (Riga et al., 2016).
Finally, Chakroborty et al. (2017) demonstrate that vortioxetine
suppresses medium spiny neuron activation in the NAc, probably
by exciting local fast-spiking interneurons. Thus, vortioxetine’s
effects on excitatory and inhibitory neurotransmission appear to
be regionally dependent.
If these premises are correct, then a plausible hypothesis
for vortioxetine’s selective potentiation of MK-801-induced
behavioral effects can be derived. Given that MK-801 has activitydependent pharmacological effects at the NMDA receptor,

Premise 2: MK-801 has receptor activation- and voltagedependent pharmacological effects.
Early studies investigating the mechanistic effects of noncompetitive NMDA receptor antagonists such as MK-801
suggest that these drugs have receptor activation- and voltagedependent pharmacological effects. Molecular pharmacology
studies demonstrate that the binding of [3 H]MK-801 is facilitated
by NMDA receptor orthosteric agonists, and by the co-agonist
glycine (Foster and Wong, 1987). Furthermore, competitive
antagonists such as 2-amino-5-phosphonovalerate reduce MK801 binding (Foster and Wong, 1987). Electrophysiological
studies have also demonstrated that MK-801’s ability to block the
NDMA receptor channel is both voltage- and NMDA receptor
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study, and thus it must be viewed with caution until more studies
can be conducted.
In light of these limitations, several suggestions for future
research can be made. First, future studies should replicate
the observations that vortioxetine does not modulate attention
function, and that vortioxetine selectively potentiates MK801’s effects, in other attention models. Future studies should
also examine whether these results can be replicated under
multiple dose combinations of vortioxetine and MK-801, and
under a regimen of chronic vortioxetine administration. Finally,
future work should evaluate which of vortioxetine’s receptor
mechanisms are involved in the pharmacodynamic interaction
with MK-801.

and that vortioxetine indirectly increases mPFC glutamate
neurotransmission, vortioxetine may potentiate MK-801 induced
attention impairments by increasing depolarization of NMDA
receptor-expressing cells, increasing access to the MK-801
binding site. This mechanism would likely be active in the mPFC
(Riga et al., 2016, 2017), a brain region that mediates at least
some MK-801 effects on attention performance (Totah et al.,
2009; Pehrson et al., 2013a; Auger et al., 2017) but is irrelevant
for MK-801’s locomotor effects. Furthermore, vortioxetine’s 5HT3 receptor-dependent disinhibitory effects would be inactive
in the NAc, which may mediate a portion of MK-801-induced
hyperlocomotion (Raffa et al., 1989; Hatip-Al-khatib et al.,
2001). Thus, it is possible that the observed selective interaction
between vortioxetine and MK-801 is caused by regionally
circumscribed increases of excitatory neurotransmission by
vortioxetine. However, it must be stressed that these ideas are
merely a theory, and more empirical research must be performed
to evaluate whether this theoretical mechanism is correct.

CONCLUSION
The current study has several notable findings. First, we observed
that acute vortioxetine treatment in unimpaired adult rodents
does not modulate performance in an attention model. We
further observed that vortioxetine selectively potentiates MK801-induced impairments in VSDT performance without altering
its effects on locomotion, and found that this interaction was not
due to altered MK-801 exposure. Given the activity-dependent
pharmacological actions of non-competitive NMDA receptor
antagonists and observations that vortioxetine increases cortical
pyramidal neuron firing, it may be that the vortioxetine-MK-801
interaction is due to a regionally selective increase in excitatory
neurotransmission, however, more research is required to test
this theory.

Limitations and Future Research
The current study is limited from several perspectives. First, as
an evaluation of vortioxetine’s effects on attention, this study
has some features that limit its translational value. Vortioxetine’s
affinity at 5-HT1A and 5-HT7 receptors is markedly lower in
rodents than in humans (Sanchez et al., 2015). Thus, if 5HT1A receptor agonism or 5-HT7 receptor antagonism modulate
mechanisms related to attention or non-competitive NMDA
receptor antagonists, then the effects observed here may not
translate to humans. Second, the limited number of MK-801 and
vortioxetine doses used in the current study do not allow for a
complete understanding of the pharmacodynamic mechanisms
controlling the observed interactions between these compounds.
Furthermore, vortioxetine is used under chronic administration
conditions in clinical situations, but was acutely administered
in the current study. Therefore, it is not clear to what
extent vortioxetine’s acute effects on attention performance are
relevant to clinical situations. Finally, the proposed mechanistic
theory regarding the pharmacodynamic interaction between
vortioxetine and MK-801 has not been properly evaluated in this
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